Abiraterone acetate and prednisone in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer: a mono-institutional experience focused on cardiovascular events and their impact on clinical outcomes | Zendy

Alessia Cavo | Zendy; A. Rubagotti | Zendy; Elisa Zanardi | Zendy; Chiara Fabbroni | Zendy; Linda Zinoli | Zendy; Antonio Di Meglio | Zendy; Eleonora Arboscello | Zendy; Andrea Bellodi | Zendy; Paolo Spallarossa | Zendy; Carlo Cattrini | Zendy; Carlo Messina | Zendy; Francesco Boccardo | Zendy

Open Access

Abiraterone acetate and prednisone in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer: a mono-institutional experience focused on cardiovascular events and their impact on clinical outcomes

Author(s) -

Alessia Cavo,

A. Rubagotti,

Elisa Zanardi,

Chiara Fabbroni,

Linda Zinoli,

Antonio Di Meglio,

Eleonora Arboscello,

Andrea Bellodi,

Paolo Spallarossa,

Carlo Cattrini,

Carlo Messina,

Francesco Boccardo

Publication year - 2018

Publication title -

therapeutic advances in medical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.272

H-Index - 49

eISSN - 1758-8359

pISSN - 1758-8340

DOI - 10.1177/1758834017745819

Subject(s) - medicine , docetaxel , abiraterone acetate , prostate cancer , prednisone , hypokalemia , androgen deprivation therapy , cohort , incidence (geometry) , proportional hazards model , hazard ratio , oncology , adverse effect , cancer , confidence interval , physics , optics

Median PFS and OS estimates and incidence of CVEs and hypokalemia in our series are consistent with those of pivotal trials of AA plus PDN, confirming the efficacy and safety of this regimen also in the real-world setting. Elderly patients have higher odds of developing/worsening CVEs. However, regardless of age, CVEs were not associated with worse outcomes. Treatment-related hypokalemia seemed to be associated with longer OS, albeit this finding needs confirmation within larger, prospective series.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research